Immune checkpoint inhibitors and prostate cancer: a new frontier?

Main Article Content

Alessandra Modena
Chiara Ciccarese
Roberto Iacovelli
Matteo Brunelli
Rodolfo Montironi
Michelangelo Fiorentino
Giampaolo Tortora
Francesco Massari *
(*) Corresponding Author:
Francesco Massari | fmassari79@gmail.com

Abstract

Despite recent advances in the treatment of metastatic castrationresistant prostate cancer (mCRPC), agents that provide durable disease control and long-term survival are still needed. It is a fact that a tumor-induced immunosuppressive status (mediated by aberrant activation of inhibitory immune checkpoint pathways as a mechanism to evade host immune surveillance) plays a crucial role in the pathogenesis of cancer, including prostate cancer (PC), making CRPC patients suitable candidates for immunotherapy. Therefore, growing interest of anticancer research aims at blocking immune checkpoints (mainly targeting CTLA-4 and PD1/PD-L1 pathways) to restore and enhance cellular-mediated antitumor immunity and achieve durable tumor regression. In this review, we describe the current knowledge regarding the role of immune checkpoints in mediating PC progression, focusing on CTLA-4 and PD1 pathways. We also provide current clinical data available, an update on ongoing trials of immune checkpoint inhibitors in PC. Finally, we discuss the necessity to identify prognostic and predictive biomarkers of immune activity, and we analyze new immune checkpoints with a role as promising targets for PC therapy.

Downloads month by month

Downloads

Download data is not yet available.

Article Details